In the Media

ISOPT Clinical speaker interviews with Touch Ophthalmology:

Ron Neumann
ISOPT Clinical 2018
Rolando & Melissa Toyos - IPL & PRP
IPL therapy and PRP eye drops for dry eye disease
Rolando & Melissa Toyos - Healthcare
The challenges of healthcare in the US
Francine Behar-Cohen - CNV
ISOPT 2018 - Challenges in the diagnosis of CNV
Baruch Kuppermann - Dry AMD
ISOPT 2018 - Challenges in the treatment of dry AMD
Baruch Kuppermann - DME
ISOPT 2018 - Integrin peptide therapy in DME
Irina Barequet - Keratitis
ISOPT 2018 - Treatment challenges in keratitis
Francesco Boscia - Anti-VEGF / DME
Anti-VEGF treatment regimens in DME
Asaf Achiron - IOP / Glaucoma
ISOPT 2018 - Lifestyle changes and IOP in patients with glaucoma
Show More

EuroTimes Series sponsored by ISOPT Clinical:

BEYOND IMAGINATION IN THE FIRST OF A NEW SERIES OF ARTICLES SPONSORED BY ISOPT CLINICAL, BARUCH D KUPPERMANN MD, PHD LOOKS AT THE REVOLUTION IN RETINAL PHARMACOLOGY

A decade ago a revolution in the way we treat and therefore conceive retinal disease took place: the introduction of anti-VEGF therapy with the concept of multiple intravitreal injections has completely  transformed wet AMD Read more

CHANGING TIMES IN THIS ARTICLE SPONSORED BY ISOPT CLINICAL, BARRETT KATZ MD, MBA LOOKS AT THE EVOLVING NATURE OF THERAPIES FOR OPTIC NEUROPATHIES

 

It was not so long ago that glaucomatologists and neuro-ophthalmologists lived in different worlds. As our understanding of glaucoma has migrated to appreciate it as, first and foremost, an optic neuropathy, these Read more

P0INT-OF-CARE TESTS IN A SERIES OF ARTICLES SPONSORED BY ISOPT CLINICAL, PENNY A ASBELL MD, FACS, MBA SAYS POINT-OF-CARE TESTING WILL ALLOW QUICKER, MORE ACCURATE DIAGNOSES

Currently, when we talk about dry eye disease (DED), we typically start with therapy that is the same for all patients – artificial tears, then maybe plugs, topical anti-inflammatories etc. Is this the best approach? Read more...

RETINAL IMAGING ISOPT CLINICAL SPONSORED ARTICLE GISÈLE SOUBRANE MD, PHD, FEBO SAYS: "ANALYSIS OF IMAGES BY EXPERIENCED OPHTHALMOLOGISTS IS CRUCIAL"

New imaging can have two meanings – either new information from the recently available imaging systems, or imaging systems resulting from new concepts. When fluorescein angiography became popular in the late 1960s, one of the indirect advantages was that ophthalmologists started to collect more documents which markedly improved the quality of the follow-up and thus the knowledge of natural history and treatment results. Read More…

DREAM TRIAL ISOPT CLINICAL SPONSORED ARTICLE ASKING WHY ARE WE TALKING ABOUT OMEGA-3 FOR DED TREATMENT? 

The expanding notion in disease today is that inflammation plays a role in nearly all diseases – not just rheumatoid arthritis, but artherosclerotic heart disease too. The peer-reviewed eye literature over the last decade shows increasing evidence of the role of inflammation in dry eye disease (DED)/ocular surface disease, in both animal models and people?(Page 15) Read more...

DRUG UTILISATION GUIDELINES FROM FDA FOR CHILDREN WITH EYE DISEASE

In an article sponsored by ISOPT Clinical, Wiley Chambers MD of the US FDA talks to Ron Neumann of ISOPT Clinical about increasing pharmacologic knowledge in children suffering from eye diseases. Read More….

Read more about ISOPT Clinical:

Diagnostic imaging can reveal new clinical endpoints but validation is required. “I think the industry is the only one who can take on such a burden using a significant number of patients in order to use imaging technology to shorten the time necessary to arrive Read more...

Global coordination sought for approval of ophthalmic devices. “Differences between the U.S. and European approval processes have resulted in discussions about the merits of both systems. Dialogue about the variations in approval processes Read more...